Dr Lal Pathlabs

Rediff.com » News » Dr Lal Pathlabs

News for Dr Lal Pathlabs

News
Business

Tackle rural spread of Covid strategically: Experts

Experts emphasise on the need to curb the spread of the novel coronavirus using strategic and pragmatic approaches in villages as well as Tier 2 and Tier 3 cities and towns, which are reporting......

Labs say capping RT-PCR rates is big blow to business

'We urge the government to have discussions with private labs on the actual cost of running a test.'Aneesh Phadnis reports. IMAGE: A health worker takes a nasal swab sample from a vegetable vendor......

'COVID-19 positive patients can be detected in 6-8 hours'

'The more people get tested, the more people will come under isolation. So the spread will get limited with testing.'. IMAGE: Doctors interact with a tourist, who has returned from Indonesia, at......

Lower input costs may aid pharma firms' Q2 margins

Analysts are expecting pharmaceutical companies to post sales growth of 10-11 per cent in the second quarter this financial year while the Ebitda (earnings before interest, tax, depreciation, and......

Q3 result preview: US, India to aid revenue growth for Pharma Inc

The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for......

US drug shortage, stable pricing set to boost pharma revenues

An acute drug shortage in the US and stable pricing along with product launches are likely to boost revenues of India’s pharmaceutical companies during the first quarter of this financial......

India business to put a spring in pharma's step

Hospitals to recover from sluggish Q3; diagnostics' growth rate at pre-Covid levels. Illustration: Uttam Ghosh/Rediff.com Analysts feel that revenue and EBIDTA growth in the pharmaceutical sector......

Estimates cut, no rerating for diagnostic companies

Brokerages have cut their estimates of listed diagnostics players for the financial year 2023-24 (FY24) after mixed December quarter results and muted near-term outlook. Photograph: Wolfgang......

Rediff News

Dr Lal Pathlabs

News for Dr Lal Pathlabs

Tackle rural spread of Covid strategically: Experts

Labs say capping RT-PCR rates is big blow to business

'COVID-19 positive patients can be detected in 6-8 hours'

Lower input costs may aid pharma firms' Q2 margins

Q3 result preview: US, India to aid revenue growth for Pharma Inc

US drug shortage, stable pricing set to boost pharma revenues

India business to put a spring in pharma's step

Estimates cut, no rerating for diagnostic companies

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS